Human papillomavirus type 16 DNA (HPV16 DNA)

Human papillomavirus type 16 (HPV16) DNA sequences constitute the circular, double-stranded genetic material of the most high-risk HPV genotype associated with human cancers (National Cancer Institute, 2023). These sequences encode essential viral proteins, most notably the E6 and E7 oncogenes, which are responsible for the degradation of host tumor suppressors p53 and pRb, leading to malignant transformation (Nature Reviews Cancer, 2002). In persistent infections, the HPV16 DNA often integrates into the host genome, causing genomic instability and constitutive expression of these oncogenes (PubMed, PMID: 30236374). As a therapeutic target, these specific DNA sequences are the focus of sequence-specific gene-editing tools like CRISPR/Cas9, which are designed to cleave and disable the viral genome to treat established lesions (Molecular Therapy, 2020). Furthermore, the detection of HPV16 DNA serves as a critical diagnostic biomarker for identifying patients at high risk for cervical and oropharyngeal carcinomas (World Health Organization, 2021). Current research also explores DNA-based vaccines that utilize these sequences to elicit a robust T-cell mediated immune response against infected cells (Journal of Virology, 2018).

Other names

HPV16 genomeHuman papillomavirus 16 DNA sequencesHPV16 nucleic acidHPV16 genomic DNA

Sequence-specific cleavage and disruption of viral oncogenes (E6 and E7) to induce cell cycle arrest and apoptosis in malignant cells, or inhibition of viral DNA polymerase to prevent replication (Molecular Therapy, 2020; PubMed, PMID: 30236374).